Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis-Reference-Cited by-同舟云学术

Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis

Published:2016-03-22 Issue:6 Volume:30 Page:2435-2450
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Black Katharine E.¹²,Berdyshev Evgeny³⁴,Bain Gretchen⁵,Castelino Flavia V.²⁶,Shea Barry S.¹²⁷,Probst Clemens K.¹²,Fontaine Benjamin A.¹²,Bronova Irina³⁴,Goulet Lance⁵,Lagares David¹²,Ahluwalia Neil¹²,Knipe Rachel S.¹²,Natarajan Viswanathan³⁸,Tager Andrew M.¹²

Affiliation:

1. Division of Pulmonary and Critical Care MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA

2. Center for Immunology and Inflammatory DiseasesMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA

3. Department of MedicineUniversity of Illinois at ChicagoChicagoIllinoisUSA

4. Department of MedicineNational Jewish HealthDenverColoradoUSA

5. PharmAkea Inc.San DiegoCaliforniaUSA

6. Division of Rheumatology, Allergy, and ImmunologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA

7. Warren Alpert Medical SchoolBrown UniversityProvidenceRhode IslandUSA

8. Department of PharmacologyUniversity of Illinois at ChicagoChicagoIllinoisUSA

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

National Center for Research Resources

National Center for Advancing Translational Sciences

Harvard University

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201500197R

Reference46 articles.

1. Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003

2. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology

3. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

4. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

5. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis;European Respiratory Review;2024-04-30

2. Recent research advances in ATX inhibitors: An overview of primary literature;Bioorganic & Medicinal Chemistry;2023-07

3. Lysophosphatidic acid, a simple phospholipid with myriad functions;Pharmacology & Therapeutics;2023-06

4. Mechanism of Lycopodii herba for RA-ILD using integrated metabolomics and network pharmacology;Analytical Biochemistry;2022-07

5. Lysophospholipid Mediators in Health and Disease;Annual Review of Pathology: Mechanisms of Disease;2022-01-24